Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 196


Nonculprit Lesion Myocardial Infarction Following Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome.

Scirica BM, Bergmark BA, Morrow DA, Antman EM, Bonaca MP, Murphy SA, Sabatine MS, Braunwald E, Wiviott SD.

J Am Coll Cardiol. 2020 Mar 17;75(10):1095-1106. doi: 10.1016/j.jacc.2019.12.067.


Effect of vorapaxar on cardiovascular and limb outcomes in patients with peripheral artery disease with and without coronary artery disease: Analysis from the TRA 2°P-TIMI 50 trial.

Qamar A, Morrow DA, Creager MA, Scirica BM, Olin JW, Beckman JA, Murphy SA, Bonaca MP.

Vasc Med. 2020 Jan 30:1358863X19892690. doi: 10.1177/1358863X19892690. [Epub ahead of print]


Response by Bergmark et al to Letter Regarding Article, "Metformin Use and Clinical Outcomes Among Patients With Diabetes Mellitus With or Without Heart Failure or Kidney Dysfunction: Observations From the SAVOR-TIMI 53 Trial".

Bergmark BA, Bhatt DL, McGuire DK, Scirica BM.

Circulation. 2020 Jan 28;141(4):e57-e58. doi: 10.1161/CIRCULATIONAHA.119.044819. Epub 2020 Jan 27. No abstract available.


Rationale and design of a navigator-driven remote optimization of guideline-directed medical therapy in patients with heart failure with reduced ejection fraction.

Blood AJ, Fischer CM, Fera LE, MacLean TE, Smith KV, Dunning JR, Bosque-Hamilton JW, Aronson SJ, Gaziano TA, MacRae CA, Matta LS, Mercurio-Pinto AA, Murphy SN, Scirica BM, Wagholikar K, Desai AS.

Clin Cardiol. 2020 Jan;43(1):4-13. doi: 10.1002/clc.23291. Epub 2019 Nov 14.


Efficacy and safety of vorapaxar for secondary prevention in low body weight in patients with atherosclerosis: analyses from the TRA 2°P-TIMI 50 Trial.

Xu H, Bonaca MP, Goodrich E, Scirica BM, Morrow DA.

Eur Heart J Acute Cardiovasc Care. 2019 Oct 23:2048872619883354. doi: 10.1177/2048872619883354. [Epub ahead of print]


Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial.

Nassif ME, Windsor SL, Tang F, Khariton Y, Husain M, Inzucchi SE, McGuire DK, Pitt B, Scirica BM, Austin B, Drazner MH, Fong MW, Givertz MM, Gordon RA, Jermyn R, Katz SD, Lamba S, Lanfear DE, LaRue SJ, Lindenfeld J, Malone M, Margulies K, Mentz RJ, Mutharasan RK, Pursley M, Umpierrez G, Kosiborod M.

Circulation. 2019 Oct 29;140(18):1463-1476. doi: 10.1161/CIRCULATIONAHA.119.042929. Epub 2019 Sep 16.


Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus.

Berg DD, Wiviott SD, Scirica BM, Gurmu Y, Mosenzon O, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Johanson P, Johansson PA, Langkilde AM, Raz I, Braunwald E, Sabatine MS.

Circulation. 2019 Nov 5;140(19):1569-1577. doi: 10.1161/CIRCULATIONAHA.119.042685. Epub 2019 Aug 31.


Quantitative EEG reactivity and machine learning for prognostication in hypoxic-ischemic brain injury.

Amorim E, van der Stoel M, Nagaraj SB, Ghassemi MM, Jing J, O'Reilly UM, Scirica BM, Lee JW, Cash SS, Westover MB.

Clin Neurophysiol. 2019 Oct;130(10):1908-1916. doi: 10.1016/j.clinph.2019.07.014. Epub 2019 Jul 25.


Metformin Use and Clinical Outcomes Among Patients With Diabetes Mellitus With or Without Heart Failure or Kidney Dysfunction: Observations From the SAVOR-TIMI 53 Trial.

Bergmark BA, Bhatt DL, McGuire DK, Cahn A, Mosenzon O, Steg PG, Im K, Kanevsky E, Gurmu Y, Raz I, Braunwald E, Scirica BM; SAVOR-TIMI 53 Steering Committee and Investigators.

Circulation. 2019 Sep 17;140(12):1004-1014. doi: 10.1161/CIRCULATIONAHA.119.040144. Epub 2019 Jul 31.


Extending i2b2 into a framework for semantic abstraction of EHR to facilitate rapid development and portability of Health IT applications.

Wagholikar KB, Ainsworth L, Vernekar VP, Pathak A, Glynn C, Zelle D, Zagade A, Karipineni N, Herrick CD, McPartlin M, Bui TV, Mendis M, Klann J, Oates M, Gordon W, Cannon C, Patel R, Aronson SJ, MacRae CA, Scirica BM, Murphy SN.

AMIA Jt Summits Transl Sci Proc. 2019 May 6;2019:370-378. eCollection 2019.


Quantitative Electroencephalogram Trends Predict Recovery in Hypoxic-Ischemic Encephalopathy.

Ghassemi MM, Amorim E, Alhanai T, Lee JW, Herman ST, Sivaraju A, Gaspard N, Hirsch LJ, Scirica BM, Biswal S, Moura Junior V, Cash SS, Brown EN, Mark RG, Westover MB; Critical Care Electroencephalogram Monitoring Research Consortium.

Crit Care Med. 2019 Oct;47(10):1416-1423. doi: 10.1097/CCM.0000000000003840.


Phenotyping to Facilitate Accrual for a Cardiovascular Intervention.

Wagholikar KB, Fischer CM, Goodson AP, Herrick CD, Maclean TE, Smith KV, Fera L, Gaziano TA, Dunning JR, Bosque-Hamilton J, Matta L, Toscano E, Richter B, Ainsworth L, Oates MF, Aronson S, MacRae CA, Scirica BM, Desai AS, Murphy SN.

J Clin Med Res. 2019 Jun;11(6):458-463. doi: 10.14740/jocmr3830. Epub 2019 May 10.


Effect of Aclidinium Bromide on Major Cardiovascular Events and Exacerbations in High-Risk Patients With Chronic Obstructive Pulmonary Disease: The ASCENT-COPD Randomized Clinical Trial.

Wise RA, Chapman KR, Scirica BM, Bhatt DL, Daoud SZ, Zetterstrand S, Reisner C, Gil EG.

JAMA. 2019 May 7;321(17):1693-1701. doi: 10.1001/jama.2019.4973.


Biomarker of Collagen Turnover (C-Terminal Telopeptide) and Prognosis in Patients With Non- ST -Elevation Acute Coronary Syndromes.

Zelniker TA, Jarolim P, Scirica BM, Braunwald E, Park JG, Das S, Sabatine MS, Morrow DA.

J Am Heart Assoc. 2019 May 7;8(9):e011444. doi: 10.1161/JAHA.118.011444.


Cardiac and Inflammatory Biomarkers Are Associated with Worsening Renal Outcomes in Patients with Type 2 Diabetes Mellitus: Observations from SAVOR-TIMI 53.

Zelniker TA, Morrow DA, Mosenzon O, Gurmu Y, Im K, Cahn A, Raz I, Steg PG, Leiter LA, Braunwald E, Bhatt DL, Scirica BM.

Clin Chem. 2019 Jun;65(6):781-790. doi: 10.1373/clinchem.2018.298489. Epub 2019 Apr 15.


Prescription of Glucagon-Like Peptide-1 Receptor Agonists by Cardiologists.

Vaduganathan M, Patel RB, Singh A, McCarthy CP, Qamar A, Januzzi JL Jr, Scirica BM, Butler J, Cannon CP, Bhatt DL.

J Am Coll Cardiol. 2019 Apr 2;73(12):1596-1598. doi: 10.1016/j.jacc.2019.01.029. No abstract available.


Vorapaxar for secondary prevention in the elderly with peripheral artery disease: Insights from the TRA 2°P-TIMI 50 trial.

Patel SM, Morrow DA, Kidd SK, Goodrich EL, Scirica BM, Bonaca MP.

Vasc Med. 2019 Apr;24(2):159-161. doi: 10.1177/1358863X19826681. Epub 2019 Mar 14. No abstract available.


Implementation of an Emergency Department High-Sensitivity Troponin Chest Pain Pathway in the United States.

Baugh CW, Scirica BM, Januzzi JL, Morrow DA, Lewandrowski KB, Jarolim P, White BA, Weinfeld MS, Hoffmann U, Nagurney JT.

Crit Pathw Cardiol. 2019 Mar;18(1):1-4. doi: 10.1097/HPC.0000000000000164. No abstract available.


Prognostic role of GDF-15 across the spectrum of clinical risk in patients with NSTE-ACS.

Zelniker TA, Jarolim P, Silverman MG, Bohula EA, Park JG, Bonaca MP, Scirica BM, Morrow DA.

Clin Chem Lab Med. 2019 Jun 26;57(7):1084-1092. doi: 10.1515/cclm-2018-1081.


Lorcaserin Safety in Overweight or Obese Patients.

Bohula EA, Wiviott SD, Scirica BM.

N Engl J Med. 2019 Jan 3;380(1):100. doi: 10.1056/NEJMc1813971. No abstract available.


Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial.

Fitchett D, Inzucchi SE, Cannon CP, McGuire DK, Scirica BM, Johansen OE, Sambevski S, Kaspers S, Pfarr E, George JT, Zinman B.

Circulation. 2019 Mar 12;139(11):1384-1395. doi: 10.1161/CIRCULATIONAHA.118.037778.


Lorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 Trial.

Scirica BM, Bohula EA, Dwyer JP, Qamar A, Inzucchi SE, McGuire DK, Keech AC, Smith SR, Murphy SA, Im K, Leiter LA, Gupta M, Patel T, Miao W, Perdomo C, Bonaca MP, Ruff CT, Sabatine MS, Wiviott SD; CAMELLIA-TIMI 61 Steering Committee and Investigators.

Circulation. 2019 Jan 15;139(3):366-375. doi: 10.1161/CIRCULATIONAHA.118.038341.


Development of an entirely remote, non-physician led hypertension management program.

Fisher NDL, Fera LE, Dunning JR, Desai S, Matta L, Liquori V, Pagliaro J, Pabo E, Merriam M, MacRae CA, Scirica BM.

Clin Cardiol. 2019 Feb;42(2):285-291. doi: 10.1002/clc.23141. Epub 2019 Jan 17.


Efficacy and safety of more potent antiplatelet therapy with vorapaxar in patients with impaired renal function.

Correa S, Bonaca MP, Scirica BM, Murphy SA, Goodrich EL, Morrow DA, O'Donoghue ML.

J Thromb Thrombolysis. 2019 Apr;47(3):353-360. doi: 10.1007/s11239-018-1779-y.


Prescriber Patterns of SGLT2i After Expansions of U.S. Food and Drug Administration Labeling.

Vaduganathan M, Sathiyakumar V, Singh A, McCarthy CP, Qamar A, Januzzi JL Jr, Scirica BM, Butler J, Cannon CP, Bhatt DL.

J Am Coll Cardiol. 2018 Dec 25;72(25):3370-3372. doi: 10.1016/j.jacc.2018.08.2202. No abstract available.


Prevalence and Outcomes of Polyvascular (Coronary, Peripheral, or Cerebrovascular) Disease in Patients With Diabetes Mellitus (From the SAVOR-TIMI 53 Trial).

Gutierrez JA, Scirica BM, Bonaca MP, Steg PG, Mosenzon O, Hirshberg B, Im K, Raz I, Braunwald E, Bhatt DL.

Am J Cardiol. 2019 Jan 1;123(1):145-152. doi: 10.1016/j.amjcard.2018.09.014. Epub 2018 Sep 26.


Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial.

Bohula EA, Scirica BM, Inzucchi SE, McGuire DK, Keech AC, Smith SR, Kanevsky E, Murphy SA, Leiter LA, Dwyer JP, Corbalan R, Hamm C, Kaplan L, Nicolau JC, Ophuis TO, Ray KK, Ruda M, Spinar J, Patel T, Miao W, Perdomo C, Francis B, Dhadda S, Bonaca MP, Ruff CT, Sabatine MS, Wiviott SD; CAMELLIA-TIMI 61 Steering Committee Investigators.

Lancet. 2018 Nov 24;392(10161):2269-2279. doi: 10.1016/S0140-6736(18)32328-6. Epub 2018 Oct 4.


Extraction of Ejection Fraction from Echocardiography Notes for Constructing a Cohort of Patients having Heart Failure with reduced Ejection Fraction (HFrEF).

Wagholikar KB, Fischer CM, Goodson A, Herrick CD, Rees M, Toscano E, MacRae CA, Scirica BM, Desai AS, Murphy SN.

J Med Syst. 2018 Sep 25;42(11):209. doi: 10.1007/s10916-018-1066-7.


Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients.

Bohula EA, Wiviott SD, McGuire DK, Inzucchi SE, Kuder J, Im K, Fanola CL, Qamar A, Brown C, Budaj A, Garcia-Castillo A, Gupta M, Leiter LA, Weissman NJ, White HD, Patel T, Francis B, Miao W, Perdomo C, Dhadda S, Bonaca MP, Ruff CT, Keech AC, Smith SR, Sabatine MS, Scirica BM; CAMELLIA–TIMI 61 Steering Committee and Investigators.

N Engl J Med. 2018 Sep 20;379(12):1107-1117. doi: 10.1056/NEJMoa1808721. Epub 2018 Aug 26.


Combination of Clinical Exam, MRI and EEG to Predict Outcome Following Cardiac Arrest and Targeted Temperature Management.

Bevers MB, Scirica BM, Avery KR, Henderson GV, Lin AP, Lee JW.

Neurocrit Care. 2018 Dec;29(3):396-403. doi: 10.1007/s12028-018-0559-z.


Safety of ticagrelor in patients with baseline conduction abnormalities: A PLATO (Study of Platelet Inhibition and Patient Outcomes) analysis.

Scirica BM, Bansilal S, Davoudi F, Armstrong PW, Clare RM, Schulte PJ, Pieper KS, Becker RC, James SK, Storey RF, Steg PG, Held C, Himmelmann A, Mahaffey KW, Wallentin L, Cannon CP; PLATO Steering Committee and Investigators.

Am Heart J. 2018 Aug;202:54-60. doi: 10.1016/j.ahj.2018.04.020. Epub 2018 May 7.


Design and rationale for the Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients-Thrombolysis in Myocardial Infarction 61 (CAMELLIA-TIMI 61) trial.

Bohula EA, Scirica BM, Fanola C, Inzucchi SE, Keech A, McGuire DK, Smith SR, Abrahamsen T, Francis BH, Miao W, Perdomo CA, Satlin A, Wiviott SD, Sabatine MS.

Am Heart J. 2018 Aug;202:39-48. doi: 10.1016/j.ahj.2018.03.012. Epub 2018 Mar 29.


Long-Term Evaluation of the Effects of Aclidinium Bromide on Major Adverse Cardiovascular Events and COPD Exacerbations in Patients with Moderate to Very Severe COPD: Rationale and Design of the ASCENT COPD Study.

Wise RA, Chapman KR, Scirica BM, Schoenfeld DA, Bhatt DL, Daoud SZ, Seoane B, Reisner C, Garcia Gil E.

Chronic Obstr Pulm Dis. 2018 Jan 24;5(1):5-15. doi: 10.15326/jcopdf.5.1.2017.0149.


Blood pressure and cardiovascular outcomes in patients with diabetes and high cardiovascular risk.

Bergmark BA, Scirica BM, Steg PG, Fanola CL, Gurmu Y, Mosenzon O, Cahn A, Raz I, Bhatt DL; SAVOR-TIMI 53 Investigators.

Eur Heart J. 2018 Jun 21;39(24):2255-2262. doi: 10.1093/eurheartj/ehx809.


Cardiovascular Outcomes According to Urinary Albumin and Kidney Disease in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From the SAVOR-TIMI 53 Trial.

Scirica BM, Mosenzon O, Bhatt DL, Udell JA, Steg PG, McGuire DK, Im K, Kanevsky E, Stahre C, Sjöstrand M, Raz I, Braunwald E.

JAMA Cardiol. 2018 Feb 1;3(2):155-163. doi: 10.1001/jamacardio.2017.4228.


Risk Assessment in Patients With Diabetes With the TIMI Risk Score for Atherothrombotic Disease.

Bergmark BA, Bhatt DL, Braunwald E, Morrow DA, Steg PG, Gurmu Y, Cahn A, Mosenzon O, Raz I, Bohula E, Scirica BM.

Diabetes Care. 2018 Mar;41(3):577-585. doi: 10.2337/dc17-1736. Epub 2017 Dec 1.


Machine Learning Improves Risk Stratification After Acute Coronary Syndrome.

Myers PD, Scirica BM, Stultz CM.

Sci Rep. 2017 Oct 4;7(1):12692. doi: 10.1038/s41598-017-12951-x.


The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors.

Butler J, Hamo CE, Filippatos G, Pocock SJ, Bernstein RA, Brueckmann M, Cheung AK, George JT, Green JB, Januzzi JL, Kaul S, Lam CSP, Lip GYH, Marx N, McCullough PA, Mehta CR, Ponikowski P, Rosenstock J, Sattar N, Salsali A, Scirica BM, Shah SJ, Tsutsui H, Verma S, Wanner C, Woerle HJ, Zannad F, Anker SD; EMPEROR Trials Program.

Eur J Heart Fail. 2017 Nov;19(11):1390-1400. doi: 10.1002/ejhf.933. Epub 2017 Aug 24. Review.


Health-related quality-of-life implications of cardiovascular events in individuals with type 2 diabetes mellitus: A subanalysis from the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR)-TIMI 53 trial.

Briggs AH, Bhatt DL, Scirica BM, Raz I, Johnston KM, Szabo SM, Bergenheim K, Mukherjee J, Hirshberg B, Mosenzon O.

Diabetes Res Clin Pract. 2017 Aug;130:24-33. doi: 10.1016/j.diabres.2016.12.019. Epub 2017 Jan 23.


Clopidogrel reloading for patients with acute myocardial infarction already on clopidogrel therapy.

Doll JA, Li S, Chiswell K, Roe MT, Kosiborod M, Scirica BM, Wang TY.

Eur Heart J. 2018 Jan 14;39(3):193-200. doi: 10.1093/eurheartj/ehx255.


First, do no (irreparable) harm: infarction, bleeding, and subsequent risk of death. The dangers of false equivalency.

Bergmark BA, Scirica BM.

Eur Heart J. 2017 Mar 14;38(11):811-813. doi: 10.1093/eurheartj/ehw639. No abstract available.


Microangiopathy, Arterial Stiffness, and Risk Stratification in Patients With Type 2 Diabetes-Reply.

Scirica BM, Braunwald E, Bhatt DL.

JAMA Cardiol. 2017 Jul 1;2(7):821. doi: 10.1001/jamacardio.2017.0164. No abstract available.


Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48).

Link MS, Giugliano RP, Ruff CT, Scirica BM, Huikuri H, Oto A, Crompton AE, Murphy SA, Lanz H, Mercuri MF, Antman EM, Braunwald E; ENGAGE AF-TIMI 48 Investigators.

Circ Arrhythm Electrophysiol. 2017 Jan;10(1). pii: e004267. doi: 10.1161/CIRCEP.116.004267.


High-Sensitivity Troponin I in Stable Patients with Atherosclerotic Disease in the TRA 2°P - TIMI 50 Trial.

Eisen A, Bonaca MP, Jarolim P, Scirica BM, White HD, Tendera M, Dellborg M, Nicolau JC, Morais J, Fox KA, Bohula EA, Murphy SA, Braunwald E, Morrow DA.

Clin Chem. 2017 Jan;63(1):307-315. doi: 10.1373/clinchem.2016.264788. Epub 2016 Nov 8.


Use of Biomarkers in Predicting the Onset, Monitoring the Progression, and Risk Stratification for Patients with Type 2 Diabetes Mellitus.

Scirica BM.

Clin Chem. 2017 Jan;63(1):186-195. doi: 10.1373/clinchem.2016.255539. Review.


Delayed Deterioration of EEG Background Rhythm Post-cardiac Arrest.

Fantaneanu TA, Sarkis R, Avery K, Scirica BM, Hurwitz S, Henderson GV, Lee JW.

Neurocrit Care. 2017 Jun;26(3):411-419. doi: 10.1007/s12028-016-0355-6.


Implementation of a Risk Stratification and Management Pathway for Acute Chest Pain in the Emergency Department.

Baugh CW, Greenberg JO, Mahler SA, Kosowsky JM, Schuur JD, Parmar S, Ciociolo GR Jr, Carr CW, Ghazinouri R, Scirica BM.

Crit Pathw Cardiol. 2016 Dec;15(4):131-137.


Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial.

Mosenzon O, Leibowitz G, Bhatt DL, Cahn A, Hirshberg B, Wei C, Im K, Rozenberg A, Yanuv I, Stahre C, Ray KK, Iqbal N, Braunwald E, Scirica BM, Raz I.

Diabetes Care. 2017 Jan;40(1):69-76. doi: 10.2337/dc16-0621. Epub 2016 Oct 17.


Effect of stimulus type and temperature on EEG reactivity in cardiac arrest.

Fantaneanu TA, Tolchin B, Alvarez V, Friolet R, Avery K, Scirica BM, O'Brien M, Henderson GV, Lee JW.

Clin Neurophysiol. 2016 Nov;127(11):3412-3417. doi: 10.1016/j.clinph.2016.09.002. Epub 2016 Sep 10.


Peripheral Revascularization in Patients With Peripheral Artery Disease With Vorapaxar: Insights From the TRA 2°P-TIMI 50 Trial.

Bonaca MP, Creager MA, Olin J, Scirica BM, Gilchrist IC Jr, Murphy SA, Goodrich EL, Braunwald E, Morrow DA.

JACC Cardiovasc Interv. 2016 Oct 24;9(20):2157-2164. doi: 10.1016/j.jcin.2016.07.034.

Supplemental Content

Loading ...
Support Center